boston745
34 minutes ago
It is therefore necessary to conjure forth their antithesis: the absurdist agent. Regular disinformation tactics render reality unknowable by blending elements of truth and falsehood to contaminate the oasis of information, but the absurdist is a specialized disinformation agent whose provocative persona attaches itself to any authentic truths he advocates. Rather than relying on logos, the absurdist employs pathos, parodying his enemy’s ideology. This serves a dual purpose: it casts an unrelenting shadow of doubt over both the agent’s assertions and his receptive audience
20. The absurdist aims to mold the public perception of himself into that of a court jester, a living caricature. Where there is an issue replete with three intersecting points of interest, the absurdist asserts that an unrelated fourth factor is relevant. He promotes factual information for extended periods, only to abruptly pivot and retract his statements. He makes wild assertions without any evidence, and he also champions data that are obviously false. He subjects himself to a series of humiliation rituals that castrate his character. Once the absurdist has established himself as cognitive dissonance incarnate, his persona discredits everything he touches, and anything he utters can be summarily dismissed as the ramblings of a madman.
Same Modis Operandi as CS101 some years back and this board is seeing it again but primarily focused on my posts with troll/bot like precision. Seen here and on Teslas board.
PioneerPhoenix73
2 hours ago
*Imagine a world where SINTX technologies have advanced so far that they can be used to create a "smooth operator" skin cream. The cream is so effective that it not only reduces hair growth but also creates a silky-smooth surface on the skin.
One day, a man named Dave, who has always struggled with unwanted hair, decides to try the new cream. After applying it to his testicles, he notices a dramatic difference within a few hours. His testicles are now so smooth that they feel like polished marble.
Excited about his newfound smoothness, Dave decides to show off his new look at the beach. As he's sunbathing, a seagull swoops down and mistakes his testicles for a giant egg. The seagull attempts to roll the "egg" away, causing Dave to jump up in surprise.
From that day forward, Dave is known as the "Smooth Operator" of the beach, and his testicles become a local legend.
The future of SintX remains extremely strong and those shareholders who have faith in god will be handsomely rewarded.
PioneerPhoenix73
2 hours ago
Debunking the Conspiracy Theory: The Bacteriostatic Behavior of Silicon Nitride
The Conspiracy Theory:
The theory posits that silicon nitride (Si3N4) has inherent bactericidal and antifungal properties due to its surface characteristics, including submicron-topography, negative charging, and chemical interactions that produce peroxynitrite.
The Scientific Counterargument:
While silicon nitride is indeed a promising material for various biomedical applications, the claim that it has intrinsic antimicrobial properties is a gross oversimplification and potentially misleading. Here's why:
1. Surface Effects are Not Sufficient:
Submicron-topography: While surface roughness can influence bacterial adhesion, it's not a direct antimicrobial mechanism. Bacteria can adapt to various surface topographies.
Negative charging: Negative surface charges can repel bacteria, but this effect is not universally observed and can be overcome by bacterial surface modifications.
Peroxynitrite formation: While peroxynitrite is a potent oxidizing agent, its formation from Si3N4 interactions is speculative and would likely require specific conditions that may not be present in all environments.
2. Hydrolysis and Ammonia Production:
Hydrolysis: While silicon nitride can hydrolyze in aqueous environments, the rate and extent of hydrolysis depend on factors like pH, temperature, and the specific composition of the material.
Ammonia production: Ammonia can indeed have antimicrobial properties, but its concentration and release rate from Si3N4 would need to be carefully controlled to ensure efficacy without causing toxicity.
3. Material Composition and Manufacturing:
Impurities: The presence of impurities or contaminants in silicon nitride can significantly influence its surface properties and biological interactions.
Manufacturing processes: The specific manufacturing methods used to produce silicon nitride can affect its microstructure, surface chemistry, and potential antimicrobial activity.
4. Complex Biological Interactions:
Bacterial strains: The antimicrobial activity of a material can vary depending on the specific bacterial strain and its virulence factors.
Biofilm formation: Biofilms are complex communities of microorganisms that can be difficult to eradicate, and their interactions with materials are influenced by multiple factors.
Conclusion:
While silicon nitride is a promising biomaterial with potential applications in various medical devices, its antimicrobial properties are likely not solely due to its intrinsic surface characteristics. The observed bactericidal and antifungal effects may be influenced by a combination of factors, including the specific composition of the material, environmental conditions, and the interactions with microorganisms. Further research is needed to fully understand the mechanisms underlying the antimicrobial activity of silicon nitride and to optimize its use in biomedical applications.
boston745
2 hours ago
Bacteriostatic behavior of surface modulated silicon nitride in comparison to polyetheretherketone and titanium
The various Si3 N4 samples showed the most favorable bacterial resistance for both bacilli tested. The mechanisms for the bacteriostatic behavior of Si3 N4 are likely due to multivariate surface effects including submicron-topography, negative charging, and chemical interactions which form peroxynitrite (an oxidative agent). Si3 N4 is a new biomaterial with the apparent potential to inhibit biofilm formation.
Antifungal activity of polymethyl methacrylate/Si3N4 composites against Candida albicans
Previous studies using gram-positive and -negative bacteria demonstrated that hydrolysis of silicon nitride (Si3N4) in aqueous suspensions elutes nitrogen and produces gaseous ammonia while buffering pH. According to immunochemistry assays, fluorescence imaging, and in situ Raman spectroscopy, we demonstrate here that the antipathogenic surface chemistry of Si3N4 can be extended to polymethylmethacrylate (PMMA) by compounding it with a minor fraction (~8 vol.%) of Si3N4 particles without any tangible loss in bulk properties. The hydrolytic products, which were eluted from partly exposed Si3N4 particles at the composite surface, exhibited fungicidal action against Candida albicans.
https://www.sciencedirect.com/science/article/abs/pii/S1742706121001641
Silicon Nitride as a Biomedical Material: An Overview
Considering its unique combination of properties, silicon nitride shows great potential for applications from both a basic research point of view and an industrial perspective. Si3N4 is a promising candidate for orthopedic implants due to its high strength, artifact-free imaging, and bio-responsiveness. It has several advantages over other commonly used biomaterials. For example, Si3N4 has a higher compressive strength than metallic biomaterials such as titanium and cobalt-chromium alloys, or biopolymers such as PEEK and UHMWPE, and a higher fracture toughness than some oxide bioceramics such as alumina. In addition to high fracture toughness, Si3N4 has a high wear resistance and a low coefficient of friction. Compared to metal implants, which produce radiological artifacts on CT or MRI scans, and PEEK, which is radiolucent, Si3N4 has favorable imaging properties and is free of artifacts on standard imaging techniques such as MRI or CT. In addition, compared to PEEK and titanium, the particular surface chemistry of Si3N4 in an aqueous environment leads it to promote bone tissue healing but inhibit bacterial proliferation. However, Si3N4 still has some disadvantages, such as brittleness, low energy dissipation, and high manufacturing cost. Currently, Si3N4 is already being used in arthrodesis devices in the cervical and thoracolumbar spine, and it is under consideration for approval in the joint arthroplasty and dental fields. Scientists and engineers have made great strides in expanding the use of Si3N4 for clinical applications and addressing various issues being faced by the industry today. Si3N4 has the potential to be microstructurally engineered and adapted to many applications, e.g., by grain size and morphology, grain boundary phase, or in a composite. We expect that further innovation of Si3N4 will come soon.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224221/
PioneerPhoenix73
3 hours ago
1. Si3N4 as a Miracle Cure
Scientific skepticism: While Si3N4 has shown promise in certain applications, claiming it can "kill most bacteria and at least the most prevalent fungi" without further research and testing is premature. It's essential to conduct rigorous scientific studies to understand its efficacy, potential side effects, and compatibility with various materials.
Regulatory hurdles: Approving new medical technologies, especially those with antimicrobial properties, involves stringent regulatory processes. The FDA and other health authorities have strict guidelines to ensure safety and effectiveness. It's unlikely that any product could be rushed to market without thorough testing and documentation.
2. WWIII and Pandemic Predictions
Unfounded speculation: Predicting the occurrence of major world events like a third world war or a pandemic is highly speculative and often based on fear-mongering. While it's prudent to be prepared for unforeseen challenges, basing business decisions on such uncertain and unproven predictions is risky.
Solar Extrema and Pandemics: The claim that pandemics are connected to solar extrema lacks scientific evidence. There's no established causal link between solar activity and the emergence of infectious diseases. Such correlations are often coincidental and can be misleading.
3. Sintx, Zimmer Biomet, and IP
Business motivations: While it's true that companies often seek to diversify their product portfolios, suggesting that Zimmer Biomet would want Sintx's IP primarily due to potential war or pandemic-related benefits is overly simplistic. There are numerous factors influencing corporate decisions, including market demand, technological advancements, and competitive landscape.
Impact on business: While pandemics and wars can undoubtedly disrupt businesses, it's important to note that many companies have shown resilience and adaptability in the face of such challenges. By implementing appropriate strategies and contingency plans, businesses can mitigate the negative impacts and capitalize on opportunities.
Conclusion
The claims presented in the conspiracy theories are largely unsubstantiated and based on speculative assumptions. While it's reasonable to explore potential applications of Si3N4 in wound care and catheter materials, it's crucial to approach such developments with a scientific and evidence-based perspective. It's also important to avoid relying on fear-mongering and unfounded predictions to guide business decisions. By maintaining a balanced and informed approach, we can better assess the potential benefits and risks associated with new technologies and market trends.
boston745
4 hours ago
Those problems present an enormous opportunity for Sintx and its partner(s) in the wound care/catherter markets. Imbuing wound care materials with Si3N4 will kill most bacteria and at least the most prevalent fungi like Candida. Coating catheters should do the same thing. However these things will take time to get to market with more testing and FDA submissions required. Thus its past-time for Sintx partner(s) in these two markets to step up, especially if WWIII is forthcoming.
If war is coming, along with another Pandemic, then its also past-time for PPE/protective apparel to get moving. If im correct about Solventum and Cardinal Health, then these two need to STEP-UP!
Global Catheter market = $55bn
Wound Care market = $22.25bn
Personal Protective Equipment market = $79.53 billion
Bill Gates says the world is facing two options: A ‘major war’ or another pandemic in less than 30 years
He cited “a lot of unrest” in the world at the moment, which could spark “a major war.”
But even if that conflict is avoided, “then yes, there will be another pandemic, most likely in the next 25 years,” Gates told CNBC Make It
There will definitely be another pandemic regardless if war occurs. Pandemics are connected to Solar Extrema. Thats why Monkeypox has been growing around Solar Max and the worst of Covid occurred around Solar Min.
Its unfortunate that war and pandemics would be good for Sintx but it also another reason why Zimmer Biomet would want the IP. Not only for diversification purposes but also because pandemics and war will hurt its business as was seen during COVID pandemic.
https://i.imgur.com/GUgo3Bb.png
Quote Source:
https://fortune.com/2024/09/10/bill-gates-fears-major-war-global-pandemic/
More on Solar Extrema and pandemics can be found here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175031022
PioneerPhoenix73
7 hours ago
Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives.
Rebuttal: While it's certainly possible, Sintx's decades of research, extensive patent portfolio, and unique formulations give them a significant competitive advantage. Developing Si3N4-based medical devices from scratch would be a costly and time-consuming endeavor for larger companies, especially given the potential challenges in replicating Sintx's proprietary technology.
Counterargument 2: Competition could lead to fierce price wars.
Rebuttal: While competition can sometimes lead to price wars, Sintx's unique value proposition and strong intellectual property position it well to withstand such pressures. Their focus on niche markets and premium products can help differentiate their offerings and maintain profitability, even in a competitive environment.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.
Rebuttal: While partnerships don't guarantee success, they can significantly accelerate market penetration and reduce risks. Collaborating with established players like Solventum provides access to distribution channels, regulatory expertise, and clinical trials, which can be invaluable in bringing new medical technologies to market.
Counterargument 4: The wound care and catheter markets are not as difficult to enter.
Rebuttal: While these markets may seem less competitive than the ortho device industry, they still have their own unique challenges. Regulatory hurdles, reimbursement issues, and the need to demonstrate clinical efficacy and safety can be significant barriers to entry. Sintx's expertise and technology give them a competitive edge in these markets.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance.
Rebuttal: Sintx is actively addressing these concerns through ongoing research and development. They are continuously working to optimize their manufacturing processes and reduce costs, while also conducting long-term studies to evaluate the durability and performance of their Si3N4-based products.
Conclusion
The potential of Sintx's Si3N4-based medical devices is undeniable. Their unique technology, strong intellectual property, and strategic partnerships position them well for long-term success. While there are challenges to overcome, the potential benefits of these devices in terms of improved patient outcomes and reduced healthcare costs make them a compelling investment.
PioneerPhoenix73
7 hours ago
Counterargument 1: The occurrence of chronic wounds is a major global health issue.
Rebuttal: While chronic wounds are a significant problem, it's important to note that they are often associated with underlying health conditions such as diabetes and circulatory disorders. Addressing these underlying issues is crucial for effective wound healing, and the role of bacteria and fungi may be overstated.
Counterargument 2: Bacteria and Fungi are a major issue for wound care leading to chronic wounds.
Rebuttal: While bacteria and fungi can contribute to chronic wound infections, other factors such as inadequate blood flow, pressure, and poor nutrition are often more significant. The focus on microbial control may be diverting attention from these underlying causes.
Counterargument 3: These exact problems are seen in the catheter industry.
Rebuttal: While catheter-related infections are a concern, it's important to acknowledge that preventive measures such as proper insertion techniques and antiseptic care can significantly reduce the risk of microbial contamination. The emphasis on microbial control may be overshadowing the importance of these preventive strategies.
Counterargument 4: Silicon Nitride is a promising material for medical applications.
Rebuttal: While silicon nitride has shown promise in certain medical applications, it's important to consider the potential limitations and challenges. For example, the long-term biocompatibility of silicon nitride in various tissues and environments needs to be further evaluated. Additionally, the manufacturing and processing of silicon nitride can be complex and expensive, which may limit its widespread adoption.
Conclusion
While the potential benefits of silicon nitride in medical applications are promising, it's crucial to maintain a balanced perspective and consider the limitations and challenges associated with its use. Overemphasizing the role of microbial control in chronic wound healing and catheter infections may divert attention from other important factors, such as underlying health conditions and preventive measures.
PioneerPhoenix73
7 hours ago
Debunking your Conspiracy Theories:
Counterargument 1: Existing medical device giants may have their own Si3N4 research initiatives or partnerships.
Rebuttal: While it's possible that larger medical device companies are conducting research on Si3N4, Sintx has a significant head start due to its decades of dedicated research and development. Their extensive patent portfolio and unique formulations would create significant barriers to entry for competitors. Furthermore, licensing Sintx's technology would likely be a more efficient and cost-effective strategy than attempting to replicate their research from scratch.
Counterargument 2: Competition could lead to fierce price wars, delaying Sintx's profitability.
Rebuttal: The current market for Si3N4-based medical devices is relatively small, with Sintx as a dominant player. While potential competition could lead to price pressure, Sintx's strong intellectual property and unique product offerings would provide a competitive advantage. Moreover, the company's focus on niche markets and value-added products could help mitigate the impact of price competition.
Counterargument 3: Collaboration with companies like Solventum doesn't guarantee product adoption.
Rebuttal: While there is no guarantee of product adoption, collaborations with established players like Solventum can provide significant benefits, such as access to distribution channels, regulatory expertise, and clinical trials. These partnerships can accelerate market penetration and increase the likelihood of commercial success.
Counterargument 4: The wound care and catheter markets are not as difficult to enter as the ortho device industry.
Rebuttal: While the wound care and catheter markets may be less competitive than the ortho device industry, they still present significant challenges. Sintx will need to demonstrate the clinical efficacy and cost-effectiveness of its Si3N4-based products in these markets to gain traction. Additionally, regulatory hurdles and reimbursement issues can also impact market entry and growth.
Counterargument 5: Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Rebuttal: Sintx is actively working to address these concerns. The company has been investing in research and development to improve the manufacturing process and reduce costs. Additionally, Sintx is conducting long-term studies to evaluate the durability and performance of its Si3N4-based products in real-world clinical settings.
Conclusion
While it's important to maintain a critical eye and consider potential risks, the evidence strongly supports the potential of Sintx's Si3N4-based medical devices to revolutionize the industry. The company's unique technology, strong intellectual property, and strategic partnerships position it well for long-term success.
boston745
17 hours ago
The occurrence of chronic wounds is a major global health issue. These wounds are difficult to heal as a result of disordered healing mechanisms. The most common types of chronic wounds are diabetic ulcers, pressure ulcers, arterial/venous ulcers and nonhealing surgical wounds. Although bacteria are an important cause of chronic nonhealing wounds, fungi also play a substantial role in them. The fungal infection rate varies with different chronic wound types, but overall, the prevalence of fungi is extremely underestimated in the clinical treatment and management of chronic wounds.
Bacteria and Fungi are a major issue for wound care leading to chronic wounds. Yet Silicon Nitride kills various bacteria and fungi which means the material embedded in wound care applicators could significantly reduce these problems.
These exact problems are seen in the catheter industry as well and thus both industries need effective anti bacterial/fungal products.
Microbe entry through catheter ports can lead to biofilm accumulation and complications from catheter-related bloodstream infection and ultimately require antimicrobial treatment and catheter replacement. Although strides have been made with microbial prevention by applying standardized antiseptic techniques during catheter implantation, both bacterial and fungal microbes can present health risks to already sick individuals.
Quote Sources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874004/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258325/
========================================
Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
PioneerPhoenix73
20 hours ago
While the potential of Sintx's technology is intriguing, let's explore some reasons why it might not translate to immediate dominance in the medical device space.
1. Partnerships Don't Guarantee Success:
Collaboration with companies like Solventum doesn't guarantee product adoption. Solventum might have other established suppliers or choose to develop their own Si3N4 technology.
Sintx relies on partners' expertise and marketing resources for product success. If a partner decides not to fully commit, it could stall product development or limit market reach.
2. Sintx Isn't the Only Player:
Existing medical device giants might have their own Si3N4 research initiatives or partnerships with other companies.
Competition could lead to fierce price wars, delaying Sintx's profitability.
3. Regulatory Hurdles:
Getting new medical devices (especially with novel materials) approved by the FDA can be a lengthy and expensive process.
Delays in regulatory approval could postpone Sintx's entry into these lucrative markets.
4. Unproven Advantages:
While research indicates the potential of Si3N4, Sintx needs to demonstrate its cost-effectiveness and long-term performance compared to established materials.
Switching to new materials requires strong clinical data and surgeon buy-in, which could take time.
5. Legal Concerns:
The claim that Sintx has "over 100 patents pending" might not fully address the issue of competition.
Other companies could develop workarounds or alternative materials that don't infringe on Sintx's patents.
Alternative Considerations:
Investigate the specific terms of Sintx's partnerships and their commitment to developing Si3N4 products.
Analyze the competitive landscape in each potential market Sintx is targeting.
Research the current regulatory environment for Si3N4-based medical devices.
A Word of Caution:
The quote from Dr. Bal about large companies acquiring smaller ones "to de-risk IP" is a possibility, but not a guarantee. Many smaller companies remain independent for years without acquisition.
Remember, the medical device market is highly regulated and competitive. While Sintx presents exciting technology, it may face a long and challenging path to becoming a dominant player.
boston745
2 days ago
NEW OPPORTUNITIES/MARKETS/PRODUCTS
Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.
All three markets mentioned here from Jan presentation are markets that Solventum sells products in.
I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days
Bryan Hanson & 3M's Solventum
wound care, oral care, health care IT, and biopharma filtration
Quote Source:
https://d1io3yog0oux5.cloudfront.net/_9be13c70ea13288f968a56d0f02f5862/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
https://www.3m.com/3M/en_US/medical-us/solutions/catheter-movement/
========================================
Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
https://www.mdpi.com/2571-6131/4/2/16/htm
========================================
Section 3 - PioneerPhoenix73 has some misinformation in its post, purposeful or not. Some factual corrections needed in its post:
1. Zimmer Biomet did not acquire Implex as Zimmer Biomet did not exist in 2003. Zimmer acquired Implex 12 years before Zimmer became Zimmer Biomet.
2. Implex material was porous version of tantalum metal it called Hydrocel and Zimmer calls Trabecular Metal. Completely different material and a metal not ceramic.
3. Sintx tech is heavily patented making it very difficult for a partner company to steal its tech. As well as any partnership agreement would likely have extra clauses to prevent such a scenario. The scenario is highly unlikely in Western countries.
4. Sintx is the only company with medical grade Si3n4 with over 100 patents pending worldwide making it unlikely that Zimmer Biomet could license the tech from any other company. Furthermore testing of products related to Sintx and Biomet IP were tested in 2016, & 2018 showing further collaberation well after that 2011 quote. Zimmer Biomet even hired a Si3N4 coatings expert end of 2018 showing continued interest past 2018. Large companies like Zimmer Biomet use small companies like Sintx to de-risk IP and then acquire it. Thats exactly how J&J operates. Does that guarantee anything? No it does not. However according to one scientist, Silicon Nitride is destined to replace current materials used in many fields of medicine.
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology. ~ Dr Sonny Bal former CEO of Sintx.
In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.
We believe we are the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility in the world, and the only provider of structural ceramics-based medical devices used for spinal fusion applications
Quote Sources:
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://d3.harvard.edu/platform-rctom/submission/a-family-of-companies-johnson-johnson/
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224011546/form10-k.htm pg 7
PioneerPhoenix73
2 days ago
1. Zimmer Biomet Acquisition of Implex Doesn't Guarantee Similar Outcome for Sintx:
The orthopaedic market landscape has changed significantly since 2003, when Zimmer acquired Implex. Competition may be fiercer, and alternative materials like highly cross-linked polyethylene might be more established.
Implex might have had a broader or more specific Si3N4 technology portfolio compared to Sintx, making a direct comparison difficult.
2. Partner Dependence Can Be a Double-Edged Sword:
Relying on partners for commercialization can limit Sintx's control over pricing, marketing, and distribution strategies.
Partner interests might not always align with Sintx's own goals. If a partner develops its own Si3N4 technology, they might prioritize it over Sintx's.
3. Hiring Former Employees Doesn't Guarantee Technology Transfer:
While these hires might have experience in relevant industries, their knowledge might be specific to their former employers' processes and technologies.
Legal restrictions might prevent them from directly transferring confidential information from their previous roles.
4. Zimmer Biomet's Past Interest Doesn't Guarantee Future Plans:
The 2011 quote about Zimmer potentially acquiring Amedica for licensing suggests their strategy might have shifted. They might be focusing on internal development or alternative partners.
Zimmer might have already licensed the key Si3N4 technology they need from Sintx and be less interested in further collaboration.
Alternative Considerations:
Look into the specific terms of any existing partnerships between Sintx and these companies. Are they licensing agreements, joint ventures, or something else?
Research the current market share and growth projections for Si3N4 in various industries beyond orthopaedics.
Analyze Sintx's own financial performance and ability to secure future partnerships to achieve its revenue goals.
By examining these points, you can build a more balanced perspective on Sintx's value proposition. Remember, past connections don't guarantee future success.
boston745
2 days ago
Zimmer Biomets mentioned for two main reasons and it is not to illustrate Sintx value. To demonstrate Sintx value, you look at Implex for a comparable materials company to get an idea of Si3n4's worth within the ortho industry only; ~230m based on a market that was 1/3rd the size it is today. You look at the industries the IP can be used in. Lastly you look at the partners Sintx appears to be working with to help it potentially commercialize its products in those industries.
One of the main reasons for mentioning Zimmer Biomet is this, to show that Sintx has large partnership to help it commercialize its products and that this particular company has been working with Sintx for going on 20 years. Sintx partnerships are key to its success due to how Sintx is setup to generate revenue: license its IP/supply blanks/powder as i said in a previous post. Its not setup to sell direct to market. This reduces costs and risk of scaling operations while also reducing maximum potential revenue. However that makes it very dependent on its partners. Thats why i used a scenario of 5% licensing fee and 5% penetration of markets that are well over 300bn in size to come up with 800m in revenue. Sintx, with its partners should be able to penetrate several of those markets far greater than 5% but i used that as an average across all those industries.
Below shows the connections to Zimmer Biomet & Morgan Ceramics/NP Aerospace. I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days. Thus i could see Solventum being one of Sintx partners in relation to Wound Care & possibly cancer related products via biofarma filtration using Si3n4 based membrane. I bring up Cardinal Health because of Sintx hire of Joseph Palomo who came from Cardinal Health R&D division. Again a potential partner in relation to PPE & Catheters.
Sintx has a pattern of hiring individuals from large companies it works with like Zimmer Biomet, possibly Cardinal Health, Morgan Ceramics. Those hires all seem to come to Sintx to help it set itself up to supply products in the same industries those companies operate in. Thus i strongly suspect they join to get Sintx ready to supply the company they came from.
Cardinal Health
Palomo joins SINTX with over 40 years of experience in protective apparel and PPE, such as surgical gowns, surgical drapes, isolation gowns, films, tubing, and surgical face masks.
https://ir.sintx.com/news-events/press-releases/detail/184/sintx-technologies-provides-update-on-antipathogenic
Bryan Hanson & 3M's Solventum
wound care, oral care, health care IT, and biopharma filtration
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
Ultrathin silicon nitride membrane with slit-shaped pores for high-performance separation of circulating tumor cells
https://pubmed.ncbi.nlm.nih.gov/35997043/
========================================
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
Silicon Nitride = Next Gen Hip implant material
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353
Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294
Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136
Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:
Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660
Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529
Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867
Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439
Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
PioneerPhoenix73
2 days ago
"While it's understandable to be skeptical about the complexities of the stock market, the claim that it's entirely controlled by a secret cabal of shadowy figures and manipulated by AI is a harmful and unfounded conspiracy theory. While there have been instances of market manipulation and insider trading, these are illegal activities that are actively investigated and prosecuted by regulatory authorities. The stock market is influenced by a variety of factors, including economic indicators, company performance, investor sentiment, and global events. While AI is increasingly used in financial analysis and trading, it's important to remember that it's a tool that is used by many different participants, not a single entity controlling the market. It's crucial to base our understanding of the stock market on factual information and avoid perpetuating harmful conspiracy theories."
boston745
3 days ago
Zimmer Biomets mentioned for two main reasons and its not to illustrate Sintx value. To demonstrate Sintx value, you look at Implex for a comparable materials company to get an idea of Si3n4's worth in the ortho industry. You look at the industries the IP can be used in. Lastly you look at the partners Sintx appears to be working with to help it potentially commercialize its products in those industries. One of the main reasons for mentioning Zimmer Biomet is this, to show that Sintx has large partnership to help it commercialize its products and that this particular company has been working with Sintx for going on 20 years. Sintx partners are important due to how Sintx is setup to generate revenue: license its IP/supply blanks/powder as i said in my last post. Its not setup to sell direct to market. This reduces costs and risk of scaling operations while also reducing maximum potential revenue. However that makes it very dependent on its partners. Thats why i used a scenario of 5% licensing fee and 5% penetration of markets that are well over 300bn in size to come up with 800m in revenue. Sintx, with its partners should be able to penetrate several of those markets far greater than 5% but i used that as an average across all those industries.
Below shows the connections to Zimmer Biomet & Morgan Ceramics/NP Aerospace. I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is CEO of Solventum and knows all about Sintx IP from his Zimmer's days. Thus i could see Solventum being one of Sintx partners in relation to PPE, catheter, &/or wound care. I bring up Cardinal Health because of Sintx hire of Joseph Palomo who came from Cardinal Health R&D division.
Sintx has a pattern of hiring individuals from large companies it works with like Zimmer Biomet, possibly Cardinal Health, Morgan Ceramics. Those hires all seem to come to Sintx to help it set itself up to supply products in the same industries those companies operate in. Thus i strongly suspect they join to get Sintx ready to supply the company they came from. Cardinal Health could be another PPE and wound care oriented partner. Solventum or Cardinal health could be working with Sintx on products for Cancer as well as a company is working with Sintx on cancer products. This could be connected to the biosensor market mentioned in my list o potential markets.
Cardinal Health
https://ir.sintx.com/news-events/press-releases/detail/184/sintx-technologies-provides-update-on-antipathogenic
Bryan Hanson & 3M's Solventum
https://news.3m.com/2023-08-22-Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
========================================
A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.
AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.
https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
Silicon Nitride = Next Gen Hip implant material
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/
Sintx - Zimmer Personel Connection
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053353
Sintx - Zimmer connection purposefully not disclosed/removed from 2013 IPO paperwork?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174144294
Sintx - Biomet R&D
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174053136
Sintx Intellectual Property is worth more than $230m as shown by Zimmers acquisition of Implex in 2003
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174493456:
Dr. Pezzotti member of Sintx scientific board and his research for Biomet
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660
Zimmer Biomet Hires Si3N4 Coatings Expert for its anti-infective dvision - December 2018
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174115529
Zimmer Biomet pays 2.5m certain R&D payment Q2 2017, Dr Bal's investment company loans $2.5m to Sintx.Q3, 2017
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174152867
Sintx - Morgan Ceramics partnership & NP Aerospace Connections
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166246
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174166439
Mr Bond, they have a saying in Chicago: 'Once is happenstance. Twice is coincidence. The third time it's enemy action'.
One is an incident, two is a coincidence, three's a pattern, and four is enough for a warrant
joev2
3 days ago
Since Zimmer is mentioned on this board nonstop, it would be interesting if Zimmer EVER mentions Sintx OR if any OTHER posters on the Zim board mention Sintx. Just saying, as I have zero interest in doing research on the matter, but have seen MANY times, small companies (and their followers) mention the big guys and their connections to them (alleged, potential, small, and imaginary large), in order to show their own values....which never seem to arrive.
PioneerPhoenix73
3 days ago
Same person. two different boards, talking to themselves.
Points to Consider:
Financial Performance: While the potential markets for SintX's silicon nitride are vast, the company's current revenue is low ($3.13 million as of Dec 31, 2023). This raises concerns about their ability to capitalize on these markets.
Technology Adoption: The theory assumes widespread adoption of SintX's technology in various industries. However, new technologies often face challenges like regulatory hurdles, competition from established players, and convincing manufacturers to adopt them.
Implex Comparison: The comparison to Implex acquisition might be oversimplified. Markets and technologies can change significantly in 20 years. Implex's success doesn't guarantee similar success for SintX.
Dilution: The high number of share offerings and reverse splits mentioned could be a sign of the company needing capital to stay afloat, potentially impacting future share value.
Alternative Explanation:
SintX might be a high-risk, high-reward investment. They have a potentially valuable technology, but they haven't yet proven their ability to turn it into a profitable business.
Here are some additional points for investors to consider:
Product Development Stage: Research progress and timelines for commercialization of SintX's products in various markets.
Intellectual Property: Strength and enforceability of SintX's patents and their ability to protect their technology.
Management Expertise: Experience and track record of the management team in bringing new technologies to market.
Conclusion:
While the theory highlights the potential of SintX's technology, a more balanced perspective considers both the potential and the risks involved. Investors should carefully research the company and its technology before making any investment decisions.
It's important to remember that this is not financial advice. Always do your own research before investing.
boston745
3 days ago
$SINT
SINT
SINTX Technologies Inc
40,786
$4.07
$0.60
(17.29%)
SINTX Technologies, Inc. engages in the development and commercialization of silicon nitride for medical and non-medical applications. It markets spinal fusion products and develops products for use in total hip and knee joint replacements. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.
Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)
Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Total = $324.26bn
Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI.
FV 100$
That account assigned fair value at $100 per share? If current OS was only $1m shares, then thats only $100m valuation. Sintx IP should exceed $230m based on what similar IP was paid for by Zimmer some 20 years ago. $230m would mean Sintx IP could only be used in the ortho market. As we can see from the list above, Sintx has many other potential markets it can enter. Sintx potential market size is well over 5x that of Implex's. Shouldnt that mean its IP is worth more than 5x what Implex IP was worth?
It looks as if the Ortho implant industry was 1/3rd that of what its worth today valued at 21bn in 2007. So would that make Sintx IP worth 15x that of Implex's? Defintely put it in the 1-3bn range @ 5x-15x.
Global market for orthopedic implants is projected to reach US$ 46.5 billion by 2017 from an estimated US$ 21.1 billion in 2007,
https://industry-experts.com/verticals/files/articles/hc003-orthopedic-implants-a-global-market-overview.pdf
========================================
In a previous post i said that if Sintx was properly valued there would not be as many offerings, shares issued per offering, or reverse splits. To show just how much its worth, first look above at the list of industries and products Sintx materials can be used for. Then research a comparable company Implex, acquired in 2003, to see how much Sintx Si3N4 is worth in the few markets that Implex Hydrocel (Zimmer's Trabecular Metal) is used in. Keep in mind that Si3n4 brings superior benefits with it compared to that of Trabecular Metal (biodegradable, antimicrobial, more osseointegrative, can be imbued and used as a coating in/on other materials), has a larger market reach as it can be used for industrial, energy, aerospace, defense, anti-pathogenic, other medical products, & even cancer treatment. Consider how much those markets are all worth. Implex couldnt touch all that but it does provide a baseline valuation for Sintx IP as it was a materials company as well.
Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.
The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.
The markets referenced here in Zimmers 10k are just a couple of markets Sintx Si3n4 can be used in.
Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.
We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.
In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.
Quote Sources:
https://www.sec.gov/Archives/edgar/data/1136869/000095013704001881/c83286e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013706002478/c02799e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013707002904/c12593e10vk.htm
Yes, yes, yes. Yes, thanks to Gavin,
EndFrame, a middle-out
compression platform,
is objectively worth $250 million.
We are a
middle-out compression platform company.
Are we worth $250 million?
Laurie couldn't vote for the platform
because she couldn't assign
a dollar value to it.
Well, Gavin has just done that.
He's validated the market,
Thus using this same logic, as Sintx is a materials company for ortho industry as Implex was, Zimmer set Sintx value for its ortho products at $232m back in 2003. With inflation in market size over the last 20 years its ortho potential is worth even more. Thats not even factoring in armor, aerospace, energy, anti-pathogenic, & other potential medtech products.
PioneerPhoenix73
5 days ago
First off, the Heikin Ashi vs. regular candle chart discrepancy. It's like comparing apples and oranges. Heikin Ashi is a fancy way of smoothing out price fluctuations, while regular candles show you the raw, unfiltered data. It's like trying to understand a complex math problem by looking at a children's picture book.
Then there's the "manipulation" theory. It's almost as if someone is trying to convince you that the stock market is a rigged game controlled by a secret cabal of shadowy figures. Newsflash: it's not. The market is driven by supply and demand, and sometimes, things just don't make sense. It's like blaming your cat for knocking over your vase when it was actually your clumsy foot.
And let's not forget the "fakeouts." It's like saying a magician's trick is "fake." Well, duh! That's the whole point of a magic trick. The market is full of "fakeouts" because that's how it works. It's like trying to predict the weather: sometimes, it's sunny, sometimes it's rainy, and sometimes it's just plain weird.
So, there you have it. A conspiracy theory debunked with logic, reason, and a healthy dose of sarcasm. Let's move on to something more productive, like discussing the merits of pineapple on pizza or the best way to fold a fitted sheet.
PioneerPhoenix73
5 days ago
I share a similar story and appreciate your conviction in debate. Salt lake city, hairdressers, electromagnetic unrest, gods messenger, saving the world, Tesla car accidents caused by space weather. UFO's made by man, Dick Van Dyke the smoking gun and every global Castrophe attributed to hutchinson effect or a weakening magnetic field brings me lots of joy :)
Alright, let's dive into this conspiracy theory, shall we? It's a bit like trying to debunk the idea that the Earth is flat: there's so much evidence against it, it's almost laughable.
First off, the "reverse merger" theory. Sure, the new CEO has experience in that, but that doesn't mean he's planning to turn Sintx into a shell company and slap a new name on it. It's more likely he's looking to leverage his experience to grow the company, not shrink it.
As for the "collaboration" or "divestment" theory, let's be real: companies don't collaborate or divest assets just because they have similar websites. It's like saying McDonald's and Burger King should merge because they both sell burgers. There has to be a strategic reason, not just a "hey, let's be buddies" attitude.
And the Zimmer Biomet thing? Oh, please. The idea that they're secretly planning to turn Sintx into a defense contractor is as ridiculous as thinking they're going to start selling moon rocks. Zimmer Biomet is a medical device company. Their bread and butter is hips, knees, and all sorts of other orthopedic stuff. Why would they suddenly want to start making tanks and missiles? It's like saying a bakery wants to start selling cars. Just doesn't make sense.
Let's be clear: Sintx is a company with unique technologies and a promising future. It's not a cash cow waiting to be milked by some big corporation. If Zimmer Biomet is interested, it's probably because they see potential in Sintx's technology for their own products.
So, there you have it. A conspiracy theory debunked with logic, reason, and a healthy dose of skepticism. Let's move on to something more productive, like discussing the weather or the latest cat videos.
PioneerPhoenix73
6 days ago
Debunking the Conspiracy Theory: Sintx and NP Aerospace
The central claim of the conspiracy theory is that Sintx and NP Aerospace are likely to merge or collaborate due to their aligned business interests and historical connections.
Key Points of Disagreement
Strategic Focus: While the theory suggests that Sintx's expansion into antipathogenic, armor, and aerospace aligns with NP Aerospace's focus, it's important to note that these are broad industries with various sub-sectors. The specific products, technologies, and market segments may not perfectly overlap.
Zimmer Biomet and Sintx: The theory posits that Zimmer Biomet's interest in Sintx is driven by a desire to diversify into the defense industry. However, Zimmer Biomet's primary focus remains in the orthopedic market, and its interest in Sintx could be more related to the company's unique ceramic technologies and potential applications in medical devices.
NP Aerospace's Expansion Plans: The theory suggests that NP Aerospace's interest in Sintx is primarily driven by a desire to expand its US presence. While this could be a factor, it's important to consider other strategic motivations, such as acquiring specific technologies or market share.
Evidence and Counterarguments
Sintx's Diversification: While Sintx has expanded into various sectors, its core competencies and strategic focus remain in materials science and ceramic technologies. Its diversification is likely driven by a desire to leverage its existing expertise in new markets rather than a fundamental shift in business direction.
NP Aerospace's Focus: NP Aerospace's primary focus on armor and medical components suggests that its strategic interests may not align perfectly with Sintx's broader diversification. While there could be potential synergies in certain areas, such as ceramic materials for armor applications, the overall fit may not be ideal.
Zimmer Biomet's Strategic Goals: Zimmer Biomet's interest in Sintx is likely driven by a desire to acquire or license specific technologies that can enhance its product offerings and market position in the orthopedic market. While a diversification into the defense industry is possible, it's not necessarily the primary motivation for its interest in Sintx.
Conclusion
While there may be some overlap between Sintx and NP Aerospace's business interests, the evidence does not support the claim that a merger or collaboration is imminent or inevitable. Both companies have their own strategic goals and priorities, and the potential for a partnership will depend on a variety of factors, including market conditions, technological advancements, and mutual benefits.
It's important to approach such conspiracy theories with a critical eye and evaluate the evidence presented. While there may be intriguing connections and coincidences, it's crucial to base conclusions on facts, logic, and evidence rather than speculation or unfounded assumptions.
boston745
6 days ago
Sintx initial focus was ortho and has since expanded to antipathogeic, armor, aerospace, and energy aligning with the focuses of NP Aerospace.
NP Aerospace is looking at expansion in the US market, hence why Sintx would be strategic for it. Sintx would have no reason to merge with NP however when it has partners like Zimmer Biomet. A joint venture or divestiture of IP could make sense in regards to armor and energy. NP's medical appears to be minor in nature to date focusing on medical beds but Sintx antipathogenic IP could be a good fit if NP wanted to expand. A scenario that would make more sense would be Sintx acquiring NP but Sintx doesnt have the resources to acquire NP nor the leadership ready for such a transaction. Sintx is setup to be acquired which is why it can operate with little staff.
NP Aerospace was divested from Morgan Ceramics, a company Sintx was already working with, at the same time Sintx pivoted to add technical. Donald Bray, whom oversaw NP Aerospace when it was part of Morgan Ceramics, joined Sintx and helped it prepare to become a supplier for Aerospace/Defense applications as well as setup armor division. That looks like Mr Bray was preparing Sintx to supply NP Aerospace in the armor market as the ceramics Sintx acquired are armor ceramics NP utilizes.
NP Aerospace: While they might be interested in expanding their US presence, their focus on armor and medical components may not align perfectly with Sintx's broader diversification.
This is precisely why NP might be looking at Sintx as most of their divisions align with NP strategic focus.
Sintx: Their strategic shift towards battery technology and other sectors suggests a different direction.
Sintx doesnt have a strategic shift towards battery technology that has been disclosed, so not sure where youre getting that. However that could be part of their technical applications. Sintx core businesses are Biomedical, Antipathogenic, Technical (Aerospace/Armor/etc.)
Zimmer Biomet is looking to diversify and has been looking at acquiring Sintx IP for licensing purposes amoungst others revenue generating purposes for quite sometime based on evidence. NP Aerospace only makes sense for Zimmer Biomet if its looking at diversifying into defense industry the way Johnson & Johnson is. Another major pandemic will hurt Zimmer Biomet's current business model and therefore it needs to expand outside of ortho. Zimmer Biomet does not necessarily need NP to achieve this as Sintx IP is extensively diversified as shown below:
Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)
Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn
Total = $324.26bn
Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market
PioneerPhoenix73
6 days ago
Divergence in Business Models:
NP Aerospace: Primarily focused on armor manufacturing, with a secondary focus on medical and energy components.
Sintx: Initially focused on armor but has since expanded into other sectors, including battery technology. This suggests a strategic shift rather than a hidden connection.
Geographical Presence:
NP Aerospace: Strong presence in the UK and Canada, with a limited US presence.
Sintx: Primarily US-based. While they might consider expanding operations, the geographical disparity makes a direct acquisition less likely.
Timeline and Acquisition Strategy:
NP Aerospace's Divestiture: Occurred in 2018, well before Sintx's entry into the armor market.
Sintx's Acquisitions: Purchases from B4C and licensing from Precision Ceramics were strategic moves to enter the armor market. A direct acquisition of NP Aerospace would have been a more straightforward approach.
Financial and Strategic Alignment:
NP Aerospace: While they might be interested in expanding their US presence, their focus on armor and medical components may not align perfectly with Sintx's broader diversification.
Sintx: Their strategic shift towards battery technology and other sectors suggests a different direction.
Zimmer Biomet's Involvement:
While Zimmer Biomet's involvement with Sintx is intriguing, it doesn't necessarily point to a direct connection with NP Aerospace. Their interests might be more aligned with Sintx's broader business strategy.
Conclusion:
Based on the available evidence, the conspiracy theory suggesting a direct connection or acquisition between NP Aerospace and Sintx appears to be unfounded. The companies have different geographical focuses, strategic directions, and timelines. While there might be indirect connections or shared suppliers within the industry, the specific claims of a conspiracy or hidden agenda lack substantial supporting evidence.
boston745
6 days ago
NP Aerospace
As indicated in my previous post, NP Aerospace was divested from Morgan Ceramics in Nov 2018. Sintx officially enters the armor market July 2021 with the purchase of assets from B4C, LLC and license from Precision Ceramics. However Donald Bray was already hard at work beginning in April 2019 in getting Sintx setup to supply aerospace and defense components.
An update to this is Sintx has officially closed its operations of its Salt Lake City armor manufacturing facility (Aug 12th). Having said that, Sintx has made no indication it plans to leave the armor market indicating a change in strategy that is currently undisclosed. It just so happens that Sintx can use one of TA&T facilities to manufacture armor and began expanding its Quality Management System to TA&T (disclosed in Jan 2024 presentation - linked below) indicating TA&T role in manufacturing will increase; TA&T has mostly been an R&D asset since its acquisition before now.
entered an asset purchase agreement with B4C, LLC of Dayton, Ohio, to acquire the equipment and technical processes required to make ballistic armor plates.
The assets acquired from B4C will be used to manufacture and market pure Boron Carbide - the highest strength ceramic armor available. These are designed to protect soldiers against hardened, high-velocity projectiles, against which other materials are not as effective. Additionally, SINTX will jointly develop and manufacture a special, lower cost composite of Boron Carbide and Silicon Carbide, under an exclusive license from Precision Ceramics USA Inc. The composite material is targeted at the law enforcement and civilian armor markets.
Incidentally NP Aerospace utilizes these exact materials for use in vehicle armor applications. Here is a quote from one of their patents listed materials used.
The outer ceramic armour layer 2 may be segmented armour and may comprise tiles or pellets of ceramic and the ceramic may be of any ballistically suitable type, including without limitation; alumina, silicon carbide, boron carbide, and composite ceramics. Typically the thickness is greater than 4 mm, but thickness depends on threat level.
NP Aerospace has manufacturing facilities in the UK & Canada but does not have manufacturing facilities in the US according to its website. It does have an office in Florida for US sales however.
We then have a Canadian facility, which is another composite manufacturing unit; we mainly manufacture body armour on that site, and we have just started to manufacture vehicle armour there as well. This is an area we are trying to grow into more over the coming months, particularly in terms of US contracts, so our partnership over there is very important. In total, for NP facilities we have about 120,000-square-feet, and partner facilities on top of that,” says David.
I do not know if the partnership is in reference to Sintx or not as NP Aerospace has multiple partner facilities it can tap to aid it handling influxes of manufacturing needed for larger orders. As Donald Bray is connected to NP Aerospace and came to Sintx to help setup this facility, it would not surprise me if Sintx was the partner being referenced here. I believe NP Aerospace wants to setup manufacturing facilities in the US so i could see it acquiring Sintx Armor subsidiary. Other scenarios ive mentioned is NP acquiring Sintx or using Sintx to help it go public via a reverse merger.
The reason i say NP acquiring Sintx or a reverse merger is a possibility is the fact that NP has an OEM medical division supplying components for medical beds as well as it supplies components for energy and transportation. These simple synergies could be the grounds for some sort of merger between the companies.
“We have diversified over the years, and extended our offering into the medical composites business, as well as some energy and transport type products. We found that offering a wider range of products has helped keep the company dynamic, as we have become more mature. That being said, we continue to have a heavy presence on the defence side of the business,” he adds.
The expansions we are forecasted to see in 2022 are likely to open up some opportunities for us in the long term, to do some really strategic acquisitions in key markets, which in turn will act as a catalyst for faster growth in certain regions. That potential is certainly there for us in the US, which is very exciting,” James concludes.
If M&A is to happen between these two companies i expect after the M&A event is finalized that Zimmer Biomets involvement with Sintx becomes more official and less behind the scenes as it is now
Quote Sources
https://ir.sintx.com/news-events/press-releases/detail/181/sintx-enters-ceramic-armor-market-through-purchase-of
https://www.freepatentsonline.com/9846013.html
https://manufacturing-today.com/news/np-aerospace/
https://d1io3yog0oux5.cloudfront.net/_9be13c70ea13288f968a56d0f02f5862/sintx/db/443/4298/pdf/SINTX+Corporate+Overview+-+Jan+%2724+-+Rev+J.pdf
boston745
6 days ago
Morgan Ceramics & NP Aerospace spin-off
2016 (earlier?), Sintx began a Ceramic-Metal Brazing project in a joint effort with later disclosed Morgan Advanced Ceramics. Sintx would use the tech for spine/knee and Morgan would use the tech created for aerospace applications. Incidentally, the February 21st, 2024 PR disclosure announcing the supply of aerospace components could be a deal to supply Morgan Technical Ceramics. If Morgan is not the "world leader in aerospace systems" mentioned in this PR, then i'd expect another announcement of such a supply deal to Morgan Ceramics. More than likely this supply deal is to Morgan Ceramics which is curiously not disclosed despite the previously disclosed collaberation with Morgan Ceramics back in 2017.
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer and developer of advanced ceramic materials and related technologies, announced today that it has entered into a 10-year, Long-Term Agreement (LTA) with a leading manufacturer of aerospace components and systems. Under the LTA, SINTX will manufacture and supply key ceramic aircraft engine components which have been qualified through a rigorous evaluation process.
“We are excited to serve our customer who is a world leader in aerospace systems,” said Dave O’Brien, Executive Vice President and Chief Operating Officer for SINTX.
https://www.morgantechnicalceramics.com/markets/aerospace/
2016 Business Update in 2017
A metal-ceramic brazing project with a global ceramics manufacturer is underway, targeting the total knee market, and composite devices in the spine market.
2017 Presentation
Enter a JDA with Morgan Ceramics
Current partnerships
Morgan Advanced Ceramics
Develop a spine device utilizing Morgan's advanced joining technologies
From my post in 2018:
Developing spine & knee implant with Morgan Ceramics. This would braze Si3N4 & unknown metal together, something Morgan specializes in. Morgan is also attempting to utilize this same technique for aerospace market. If successful Morgan would commercialize and sell to entitties like NASA. No signed JDA we are aware of.
According to the September 2017 presentation, Sintx had some sort of partnership with Morgan Ceramics but had not officially signed a JDA with them. A JDA was never disclosed buts its possible that a NDA kept this information from being disclosed. A JDA would explain why Mr. Donald Bray joined Sintx in 2019 as he left Morgan Ceramics when it sold NP Aerospace, aka his position was no longer needed without NP Aerospace divisions. More on this in a minute.
After months of financial, legal and company due diligence, we finalised the deal towards midnight on November 20th
April, 15th 2019 6 months after NP Aerospace was sold off, Sintx announced that Donal Bray would join Sintx, a former VP from Morgan Advanced Ceramics who also oversaw the NP Aerospace division as a business director.
SINTX Technologies, Inc. (NASDAQ: SINT) announced today that it has hired Donald J. Bray as Vice President of Business Development. Mr. Bray was formerly Vice President of Technology at Morgan Advanced Materials, where he focused on leading strategic initiatives into new market areas. Mr. Bray will assume the new role at SINTX on 22 April 2019.
Business Director, Armor Jan 2008 - Sep 2014 6 yrs 9 mos
NP Aerospace, the world’s most advanced, composite armor company, has incorporated in the United States to provide advanced, composite tactical and combat-armored systems for vehicles and personal protection systems specifically for the U.S. military.
Mr. Donald Bray comes into Sintx, aids setting up Sintx for ISO 9100D certification, aids in the acquisitions of armor and TA&T technical assets, and then leaves Sintx once armor facility is brought online remaining as a consultant. This to me suggests that Mr. Bray was sent to Sintx to aid in getting Sintx ready so it could supply armor components for NP Aerospace and aerospace components for Morgan Ceramics.
October 2018, Sintx shed Amedica and some old IP and became Sintx Techolgies where it began branching from solely a medical implant company to more of a materials company. At which point it began focusing on the development of industrial and aerospace components. A little over a month later, NP Aerospace & subsidiaries were sold off from Morgan Ceramics November 20th, 2018. April 2019 Bray joined Sintx in 2019 to prep Sintx for manufacturing certificates, sales in defense, aerospace markets, and acquire IP. If the two companies combine thats an odd way to do a joint venture.
https://i.imgur.com/slfDxL5.jpeg
Quote Sources:
https://ir.sintx.com/news-events/press-releases/detail/223/sintx-technologies-enters-into-a-second-long-term-supply
https://ir.sintx.com/news-events/press-releases/detail/100/correction---amedica-releases-2016-preliminary-unaudited
https://web.archive.org/web/20221128231656/https://static.seekingalpha.com/uploads/sa_presentations/787/14787/original.pdf - Slides 5 & 27
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139366206
https://battle-updates.com/wp-content/uploads/2021/08/BSTC4iStar-Sep-2021-Digital.pdf
https://ir.sintx.com/news-events/press-releases/detail/129/sintx-technologies-hires-strategic-vp
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167887649
PioneerPhoenix73
1 week ago
Debunking the Conspiracy Theory about Dr. Pezzotti and Biomet Liners
The theory suggests Dr. Pezzotti's research on Biomet liners after joining Sintx's scientific board in 2015 is a conflict of interest and evidence of manipulation. Here's why this theory doesn't hold water:
1. Longstanding Research Focus: Dr. Pezzotti's research on UHMWPE liners, specifically Biomet liners, began in 2007, well before joining Sintx. This indicates his research focus wasn't influenced by Sintx but rather reflects a long-term interest in the topic.
2. Focus on Improvement: Many of Dr. Pezzotti's studies compare different generations of Biomet liners (ArCom vs. ArComXL vs. E1). This suggests his research aimed to understand how material properties affect wear and potentially improve liner performance, not to hide flaws.
3. Transparency in Manufacturing: The studies explicitly mention Biomet as the manufacturer of the liners analyzed. This transparency indicates no attempt to disguise the origins.
4. Collaboration is Common: It's standard practice for researchers to collaborate with companies in their field. Companies often provide materials for research, while researchers offer independent evaluation. This collaboration benefits both parties and ultimately advances scientific knowledge.
5. Dr. Pezzotti's Research on Other Companies: While Dr. Pezzotti has focused on Biomet liners, his 2015 study also included a zirconia femoral head from another company (Saint-Gobain Desmarquest). This further suggests his research isn't solely focused on promoting Biomet products.
6. Regulatory Oversight: Hip implant testing and approval are subject to rigorous regulations by agencies like the FDA. These processes ensure that new materials and designs undergo thorough evaluation before reaching patients, regardless of research collaborations.
In conclusion: The evidence suggests Dr. Pezzotti's research on Biomet liners reflects a long-standing interest in improving hip implant technology. Additionally, collaboration between researchers and companies is a normal and valuable practice in scientific advancement. Regulatory oversight ensures new implant materials are rigorously tested before use.
boston745
1 week ago
You said previously they can disguise trades in a myriad of ways so this would be just an example of that if thats what happened. If thats what happened its so shares could go where they want them to go without it being known by retail. That could be for good or bad reasons depending on intent.
========================================
Here are some of the studies Dr. Pezzotti did before and after he joined Sintx Scientific board in 2015. You'll see multi-year consistent research into liners for use in hip implants, specifically relating to Biomet liners. This is not a comprehensive list but represents alot of work done by Dr Pezzotti on behalf of Biomet; part of the Zimmer-Biomet family of companies as of 2015. Dr. Pezzotti has been a major contributor to scientific research and testing for Sintx. Example of a shared resource between companies imo. Dr Pezzotti was also consultant for the 2016 study pertaining to Sintx femoral head and Biomets liner that occurred a decade after the last study involving these two companies head and liner.
Amedica Corporation Adds Giuseppe Pezzotti, PhD to Its Scientific Advisory Board
https://ir.sintx.com/news-events/press-releases/detail/53/amedica-corporation-adds-giuseppe-pezzotti-phd-to-its
2007
Confocal Raman spectroscopic analysis of cross-linked ultra-high molecular weight polyethylene for application in artificial hip joints
One new [Fig. 1(A)] and two retrieved cross-linked UHMWPE acetabular cups [Figs. 1(B) and 1(C)] were investigated. The two retrieved acetabular cups were obtained at the time of revision surgery from total hip arthroplasty. All the acetabular components investigated in this study were manufactured by Biomet Japan Incorporated (Tokyo, Japan). New acetabular components (ArCom®, Biomet Incorporated) were made from GUR 1050 bar stock by isostatic compression molding (with no addition of calcium stearate) and successive surface irradiation by a ? -ray dose of 33kGy
2010
Raman tensor analysis of ultra-high molecular weight polyethylene and its application to study retrieved hip joint components
The short-term retrieved acetabular components were both made of highly cross-linked polyethylene, manufactured from 1900H bar stock by isostatic compression molding (with no addition of calcium stearate) (ArComÒ, Biomet Japan Inc., Tokyo, Japan
2011
Structural profile of ultra-high molecular weight polyethylene in acetabular cups worn on hip simulators characterized by confocal Raman spectroscopy
Thus, we compared acetabular cups made of two types of polyethylenes, the old ArCom® and new ArComXL™.
Two types of acetabular cups were examined, which were both manufactured by Biomet Inc., Warsaw, IN.
2012
In-Depth Oxidation and Strain Profiles in UHMWPE Acetabular Cups Non-Destructively Studied by Confocal Raman Microprobe Spectroscopy
One new and four retrieved cross-linked UHMWPE acetabular cups have been investigated. The four retrieved acetabular cups were obtained at the time of the re-spective hip arthroplasty revision surgeries. All acetabular components (ArCom ® , Biomet) were made from 1900H bar stock by isostatically direct compression molding and surface irradiated by a ? -ray dose of 33 kGy.
2014
Strain-induced microstructural rearrangement in ultra-high molecular weight polyethylene for hip joints: A comparison between conventional and vitamin E-infused highly-crosslinked liners
Three types of acetabular liners were analyzed, which had gone through a different manufacturing process. All liners had a diameter of 32 mm and were provided by Biomet Inc., Warsaw, IN, USA. One type of liner was the newly launched liner E1®, available on the international market since 2007. Another type of component belonged to a former generation of polyethylene, the brand ArCom®, which was clinically introduced in 1995 and it is currently commercially available.
2015
Environmental Stability and Residual Stresses in Zirconia Femoral Head for Total Hip Arthroplasty: In Vitro Aging versus Retrieval Studies
The 28?mm sized 3Y-TZP femoral heads (n = 3) were provided by Biomet Inc. (Warsaw, IN). These were manufactured by Saint-Gobain Desmarquest Inc. (Evreux, France). These heads were distributed with the trade name of Prozyr (currently out of market since 2001).
2018
Do rim cracks and backside grinding affect the aging kinetics of alumina-matrix composite acetabular liners?: DO CRACKS AND GRINDING AFFECT THE AGING KINETICS IN AMC LINERS?
Schematic cross-section representation of the AMC (BIOLOX® delta) acetabular system (G7®, Zimmer Biomet G.K., Tokyo, Japan).
Quote Source:
2007 https://www.spiedigitallibrary.org/journals/journal-of-biomedical-optics/volume-12/issue-01/014011/Confocal-Raman-spectroscopic-analysis-of-cross-linked-ultra-high-molecular/10.1117/1.2710247.full#_=_
2010 https://iris.unive.it/retrieve/61fda02d-dae7-49bb-9850-7201c02d3a6a/Raman_tensor_analysis_of_ultra-high_molecular_weight_polyethylene_and_its_application_to_study_retri.pdf
2011 https://onlinelibrary.wiley.com/doi/full/10.1002/jor.21331
2012 https://iris.unive.it/bitstream/10278/5018766/2/In-Depth_Oxidation_and_Strain_Profiles_in_UHMWPE_Acetabular_Cups_Non-Destructively_Studied_by_Confoc.pdf
2014 https://www.sciencedirect.com/science/article/abs/pii/S175161611200344X
2015 https://pdfs.semanticscholar.org/1f69/d96c2ec91f33070939ff9784aca088fd970f.pdf
2018 https://www.researchgate.net/figure/a-Schematic-cross-section-representation-of-the-AMC-BIOLOXR-delta-acetabular-system_fig1_327874215
PioneerPhoenix73
1 week ago
1. Dark Pool Volume and Forum Shutdown
Dark Pool Volume: The significant decrease in dark pool volume could be attributed to various factors, including increased market volatility, changes in investor behavior, or regulatory interventions. It does not necessarily indicate a nefarious conspiracy.
Forum Shutdown: The closure of a forum could be due to a variety of reasons, such as a decline in user activity, changes in company policy, or technical issues. It's speculative to link this to the removal of posts related to bot identification.
2. Sintx-Biomet Collaboration and Research
Timeline and Collaborations: The timeline of collaborations between Sintx and Biomet aligns with the development of medical devices and research in the field. The involvement of Dr. Bal and Dr. Pezzotti in studies involving Biomet IP is consistent with academic and industry partnerships.
JDA and Research: The Joint Development Agreement (JDA) and subsequent research projects are within the realm of normal business practices for companies in the medical device industry. The testing and publication of research findings are essential for product development and validation.
3. Patent and Research Findings
Patent and Research: The patent and research findings related to silicon nitride coatings and femoral heads align with ongoing advancements in orthopedic implants. The comparison of different materials and techniques is a standard practice in scientific research.
Scientific Analysis and Counterarguments
Dark Pool Volume: While a significant decrease in dark pool volume can be intriguing, it's essential to consider broader market trends, regulatory changes, and investor sentiment to provide a comprehensive explanation.
Forum Shutdown: The closure of a forum without a clear explanation is speculative. It could be due to various reasons, including company policies, technical issues, or a decline in user engagement.
Sintx-Biomet Collaboration: The collaborations and research projects between Sintx and Biomet appear to be legitimate and aligned with industry standards. The involvement of academic researchers and the publication of findings support the scientific nature of the work.
Patent and Research: The patent and research findings related to silicon nitride coatings and femoral heads are consistent with ongoing advancements in orthopedic implants. The comparison of different materials and techniques is a standard practice in scientific research.
Conclusion
Based on the information provided, the conspiracy theory lacks substantial evidence to support its claims. The events and collaborations described appear to be within the realm of normal business practices and scientific research. It's important to approach such theories with a critical eye and rely on verifiable facts and evidence.
boston745
1 week ago
Whats especially interesting is the amount of volume generated solely from dark pool. Normally that makes up 70-80% of the daily volume but that day it was -97%.
Oh and apparently theres no talking about how to identify bots on the VIP forum because those posts were removed and the forum has suddenly been shutdown after posting that. I guess ihub wants the bots that spread disinformation or doesnt want the CEO to know.
========================================
Looks like the connections between Sintx and Biomet on the R&D front goes all the way back to before 2007 when the company first tried to IPO. This study would have began in 2006 just after Dr. Bal joined Sintx as a clinical advisor.
2007 (ORS Annual Meeting Feb 11-14)
THERMAL CONDUCTIVITY OF FEMORAL BALL STRONGLY INFLUENCED UHMWPE WEAR IN A HIP SIMULATOR STUDY
Ten 28 mm ID isostatically moulded UHMWPE liners were investigated: GUR 1050 resin, gamma-sterilized with 25ñ40 kGy in argon (ArComô, Biomet Inc, Warsaw, IN). The liners were coupled with zirconia (Y-ZrO 2 : ProzyrÆ), cobalt-chrome (Biomet, Inc), silicon nitride (Si3 N 4 : Amedica-Inc, UT) and alumina femoral balls (Al2 O 3 : Biolox-forteÆ) (Figure 1).
Acknowledgements The authors thank Amedica, Utah, US and Biomet Inc, US for their support
2015 - Signed JDA
In 2015 Sintx signed a JDA with a company to develop Si3N4 based devices. Since that time there has been no disclosure of product develop containing IP with any other company other than whats been used with Biomet IP. Furthermore, that product containing Biomet IP was tested at a facility Biomet was using for product testing. The JDA was signed before Dr Pezzotti joined Sintx's Scientific Board Sept 2015. It just so happens that Dr Pezzotti has done at least 7 sceintific studies involving Biomet IP from 2007 onward. This suggests that the JDA included sharing research talent.
I have always thought this R&D agreement was connected to Zimmer. If it was indeed signed with Biomet, it was signed in May just a month before the merger between Zimmer and Biomet officially closed June 24th. The timing of which i always felt was suspect and purposeful.
To kick off things there is the JDA that was not revealed until Sept 2017 on the delayed 10K filing.
On May 13, 2015, the Company entered into a joint agreement for research and development of silicon nitride based devices. This agreement is effective for a period of five years from the date of commencement. The Company incurred payments of $270,000 and $270,000 related to this agreement for the years ended December 31, 2016 and 2015, respectively.
Next, on the 2015 10k, its reveled that they have initiated testing of their femoral head with a strategic partner that is to run into 2016. This seems to reference the testing that was occurring at the University of Nebraska over that same period; a facility Biomet had tapped repeatedly to test. That said Biomet is not the only company to use this facility.
Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. This testing is expected to continue through 2016. If the tests indicate that silicon nitride femoral heads are superior in terms of wear performance, taper corrosion, strength and in vitro hydrothermal stability, we eventually intend to commercialize this product in cooperation with a strategic partner.
During that same period of time Sintx just happened to fund (partially fund?) a study testing its femoral head at the University of Nebraska the same location that Biomet uses for some of its testing. By itself could just be a coincidence but coupled with other connections it looks like Biomet is the reason this testing is going on at this location.
Amedica - Comparative Testing of Ceramic Femoral Heads for Total Hip Arthroplasty, 2015-2016
Separately, it seems, another study was underway in Japan testing Sintx femoral Head and Biomet's E1 liner, for which Zimmer Biomet supplied for testing. 2020, that testing was officially published.
2017
comparative hip simulator study examining the wear behavior of an advanced highly cross-linked and vitamin E stabilized polyethylene (E1® Zimmer-Biomet, Warsaw, IN, USA)
Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research.
Published study on this testing:
Wear Simulation of Ceramic-on-Crosslinked Polyethylene Hip Prostheses: A New Non-Oxide Silicon Nitride versus the Gold Standard Composite Oxide Ceramic Femoral Heads
Last we have publication of another component which involved Sintx using Biomet's G7 shell to test its Si3n4 coating tech. The only thing missing from a hip implant is a femoral stem. This could be the final component being worked on with Sintx collaboration with 3DCeram Sinto to perfect 3D printing of a Si3n4 which would allow Sintx to print a porous femoral stem that has a much lower modulus of elasticity.
2019
3D-additive deposition of an antibacterial and osteogenic silicon nitride coating on orthopaedic titanium substrate
Zimmer Biomet G7 OsseoTi Limited Actabular Shell (4 Hole) - Si3N4 Coated
Patent
Although a direct comparison between the two types of UHMWPE liners (i.e., X3 v. E1.RTM.) has yet to be made, it appears that the amount of surface oxidation associated with the E1.RTM. liners was about one order of magnitude lower than the X3 in spite of the fact that the E1.RTM. liners had .about.10 times the number of testing cycles. Nevertheless, an increase in the oxidation index for the E1.RTM. liners coupled to ZTA heads was a tangible result of this Example. With 5 million cycles being kinematically equivalent to about 2.5 years in vivo, it appears that addition of vitamin-E does not completely eliminate liner oxidation in artificial hip joints coupled to oxide ceramics.
Quote Sources:
1. http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/265/660/pdf/0278.pdf
2. https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm pg F-24
3. https://www.sec.gov/Archives/edgar/data/1269026/000149315216008221/form10-k.htm pg 12
4. https://web.archive.org/web/20230519175028/http://www.unmc.edu/orthosurgery/research/grants.html
5. https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
6. https://www.mdpi.com/1996-1944/13/13/2917
7. https://www.sciencedirect.com/science/article/abs/pii/S1751616119309099
8. https://uspto.report/patent/app/20190307569
PioneerPhoenix73
1 week ago
Market Manipulation: If SINT is indeed highly manipulated, the "accumulation" could be a deliberate tactic to deceive investors. The perpetrators might be trying to create a false sense of weakness to drive down the price before a pump-and-dump scheme.
Profit-Taking: The high volume could simply be a result of profit-taking by investors who bought at lower prices. As the price rises, some investors may decide to sell to secure their gains, leading to increased volume.
Algorithmic Trading: Advanced algorithms can execute trades at high speeds, often leading to sudden spikes in volume. These algorithms might be responding to market signals or following pre-programmed strategies, which could contribute to the price movement.
Fundamental Factors: While not as immediately apparent as technical indicators, underlying fundamental factors could also be influencing the price. For example, a negative news announcement, a change in company leadership, or a decline in earnings could lead to selling pressure and a drop in price.
Conclusion:
While the Heikin Ashi chart might suggest accumulation, it's important to consider other factors and potential explanations. The stock market is a complex environment, and it's often difficult to definitively determine the underlying reasons for price movements. It's essential to conduct thorough research and analysis before making investment decisions.
boston745
1 week ago
Sintx - Zimmer Personel Connection
Meanwhile on the Personnel side of things, Centerpulse & then Zimmer has been involved. This does not represent an exhaustive list of personnel connected between the two companies, only to highlight that someone connected to Zimmer (before it Centerpulse) has been at the helm of Sintx since its founding.
Founded 1996
Dr. Hofmann, MD
Aaron A. Hofmann, M.D. is our co-founder and has been a member of our board of directors since 1996. Dr. Hofmann is a nationally and internationally recognized orthopedic surgeon, known for his accomplishments in developing total hip and knee replacement systems, innovative surgical approaches in hip and knee surgery and basic research on human bone dynamics. Dr. Hofmann holds 14 patents, many of which are directed at inventions involving hip and knee implants. Since 2003, Dr. Hofmann has been a design surgeon for Zimmer Holdings, Inc., the largest orthopedics company in the world. Dr. Hofmann, working with a team of orthopedic surgeons, helped design Zimmer’s new gender knee specifically designed for women.
Centerpulse Orthopedics Inc., an Austin-based subsidiary of Switzerland-based Centerpulse AG [NYSE: CEP], on Tuesday unveiled the Natural-Knee Unicompartmental System Instrumentation for partial replacement of the knee joint.
Dr. Aaron Hofmann, an orthopedic surgeon at the University of Utah Medical Center who helped design the Natural-Knee system
Oct 2003
Dr. Max Link, PHD (Chairman 2003-2014)
Max Link, Ph.D. has served as the Chairman of our board of directors since October 2003. Dr. Link served as Chairman of the Board and Chief Executive Officer of Centerpulse AG, the largest orthopedics company in Europe, from March 2002 until October 2003, when Centerpulse was acquired by Zimmer Holdings, Inc. Prior to joining Centerpulse,
The above quote was from Sintx first attempt to IPO in 2007. Now im going to reference another blurb about Dr Link from the 2014 IPO fillings. Notice anything missing?
Max E. Link, Ph.D. has served as the chairman of our board of directors since October 2003. Dr. Link was chairman of the board of directors and Chief Executive Officer of Centerpulse AG, a medical implant company from March 2002 to October 2003. Prior to joining Centerpulse,
Looks like, for some reason, connections between Sintx and Zimmer was purposefully withheld in the 2014 IPO paperwork. Also, in the description of current CEO Dr. Bal, there is no mention of him being a surgeon designer for Zimmer the way this fact was mentioned about Dr. Hofmann on the 2007 IPO paperwork. This despite Dr. Bal's extensive resume showing him as such. Ive included other supportive evidence showing he was a paid consultant for Zimmer. Why do you think this information was withheld at IPO? Certainly if Sintx was a scam, as some like to claim, it would have leaned harder on this information instead of hiding it wouldnt you think?
2012 - Dr Sonny Bal, MD, JD, MBA, PHD joins Sintx board of directors
B. Sonny Bal, M.D. has served on our board of directors since February 2012. Dr. Bal is Professor & Chief of Adult Reconstruction at the University of Missouri, Columbia, specializing in hip and knee replacement surgery. He also is an Adjunct Professor of Material Sciences at the University of Missouri at Rolla. Dr. Bal is a member of the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons. Dr. Bal received his M.D. degree from Cornell University and an M.B.A. from Northwestern University, and a J.D. from the University of Missouri. Dr. Bal is a licensed attorney and co-founder of the Bal Brenner law firm in North Carolina.
We believe that Dr. Bal’s expertise in orthopedic surgery and his specialty in hip and knee replacement surgery qualifies him to serve on our board of directors.
2014 - Dr Bal becomes Chairman & CEO
Dr. Sonny Bal, MD
Designer Surgeon Panel, Zimmer Inc., Warsaw, Indiana, 2002 to present.
Total Joint Reconstruction Clinical Advisory Panel, Amedica Inc., Salt Lake City, UT, 2005 to present.
Zimmer Holdings, Inc.: “Comparison of tissue-engineered osteochondral grafts fabricated with mesenchymal stem cells and trabecular metal or allograft bone.” $125,406.00. 5/25/2006 to 5/24/2007.
Zimmer Holdings,Inc.: “Design and testing of a canine biological femoral head replacement.” $342,837.00. 7/1/2011 to 6/30/2014.
AAOS meeting Feb 2011
In accordance with ACCME guidelines, all participants in the Annual Meeting must have disclosed on or after February 7, 2011. The disclosures
in this list are in compliance and current with the AAOS Disclosure database as of October 1, 2011.
B. Sonny Bal, MD: 1, 3B – Zimmer; 3C – OMNI, Amedica, Salient, ConforMIS;
4 – Amedica
3a. – Employee
3b. – Paid consultant
3c. – Unpaid consultant
4 – Stock or stock options; or
Quote Sources:
1. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 74
2. https://web.archive.org/web/20060126100849/https://www.bizjournals.com/austin/stories/2002/12/02/daily15.html
3. https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 73
4. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 89
5. https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 90
6. https://web.archive.org/web/20240316192627/https://hipandknee.com/wp-content/uploads/2014/04/Dr.-Bal-CV.pdf
7. https://web.archive.org/web/20120602234429/https://www.aaos.org/Education/anmeet/education/Disclosures.pdf
My old link to Dr Bal's 2013 resume experienced a 404 error. Fortunately i found a working link and archived it this time.
PioneerPhoenix73
1 week ago
Sintx and Zimmer Biomet:
You've found connections between these companies. That doesn't automatically mean a conspiracy. Maybe they collaborate on research or share expertise – a good thing, right?
Disclosure of connections? Financial filings have specific requirements, but sometimes details get buried. Digging deeper is good, but focus on facts, not assumptions of hidden agendas.
Sintx Intellectual Property:
Valuable IP is great, but did Sintx actually leverage it? Companies buy patents all the time – it doesn't guarantee success.
People and their affiliations:
Someone working for both companies? Not unusual. People move between jobs, bringing knowledge and experience.
Suspicious timing of payments? Look for concrete evidence – was there a clear connection between the R&D payment and the loan? Coincidence is a possibility.
Sintx Partnerships:
Partnerships are how companies expand and grow. Investigate the nature of the partnerships – are they legitimate collaborations or something more?
Tesla
"Fake it till you make it"? Tesla has achieved impressive things. Challenges exist with any new technology, but progress is undeniable.
Federal investigations? These happen all the time (remember, some investigations lead to nothing). Look for official information, not internet speculation.
9/11 Conspiracy Theories:
These are well-trodden ground. There's overwhelming evidence against these theories. Trust credible sources, not internet rabbit holes.
Climate Change:
Earth's magnetic field fluctuates, but that's not causing climate change. Scientific consensus overwhelmingly points to human activity as the culprit. Listen to the experts.
Pandemics and Solar Activity:
Solar activity can influence weather, but it's not causing pandemics. Viruses and bacteria are the real culprits, not sunspots. Trust medical science.
Flying Saucers:
This is a fun one for sci-fi fans, but there's no evidence to support man-made UFOs.
Look, healthy skepticism is good, but don't let it lead you down a path of wild theories. Research from credible sources, and be open to evidence that contradicts your initial beliefs.
Remember, the truth is often far less interesting than a good conspiracy theory, but it's usually more accurate.
And finally, a friendly tip: Chasing conspiracies can be a time-consuming rabbit hole. Maybe use that energy to learn something new about a topic that genuinely interests you!
PioneerPhoenix73
1 week ago
Alright, let's dive into the world of "divine dental implant migraines."
So, you're telling me this guy, a self-proclaimed "god messenger," thinks that electrostatic fields from dental implants are causing people to have migraines? Well, let's just say that's about as accurate as saying the moon is made of cheese.
First off, let's talk about the science. Electrostatic fields are created by the separation of electric charges. Now, while it's true that dental implants can have metal components, the idea that these components are generating enough of an electrostatic field to cause migraines is about as likely as a squirrel riding a unicycle to the moon.
Secondly, let's consider the evidence. Where are the scientific studies supporting this claim? I'm pretty sure if a dental implant was causing widespread migraines, there would be a line of scientists, doctors, and lawyers banging on the door of the FDA, demanding action. But nope, nothing. Just one guy, claiming to be a divine messenger, spouting nonsense.
And finally, let's address the "no societal rewards" part. Oh, please. If this guy truly believed he was saving lives, wouldn't he be jumping at the chance to get his "miracle cure" out there for everyone? It's almost like he's more interested in attention and a sense of self-importance than actually helping people.
So, to our "divine messenger" friend: If you're really so concerned about people's suffering, why don't you try something more practical, like volunteering at a soup kitchen or donating to a charity? And while you're at it, maybe consult a dentist about your dental implants. They might be able to tell you something that doesn't involve celestial beings and electrostatic fields.
PioneerPhoenix73
1 week ago
Boston745 says: Thats ultimately what i want to see happen. Its best for everyone imo. Its not just about money for me. I want to see the products helping people like Mr Van Dyke or of course my wife. I get riled up when i think somethings messing with that.
So, you're telling me this guy, a self-proclaimed "god messenger," thinks that electrostatic fields from dental implants are causing people to have migraines? Well, let's just say that's about as accurate as saying the moon is made of cheese.
First off, let's talk about the science. Electrostatic fields are created by the separation of electric charges. Now, while it's true that dental implants can have metal components, the idea that these components are generating enough of an electrostatic field to cause migraines is about as likely as a squirrel riding a unicycle to the moon.
Secondly, let's consider the evidence. Where are the scientific studies supporting this claim? I'm pretty sure if a dental implant was causing widespread migraines, there would be a line of scientists, doctors, and lawyers banging on the door of the FDA, demanding action. But nope, nothing. Just one guy, claiming to be a divine messenger, spouting nonsense.
And finally, let's address the "no societal rewards" part. Oh, please. If this guy truly believed he was saving lives, wouldn't he be jumping at the chance to get his "miracle cure" out there for everyone? It's almost like he's more interested in attention and a sense of self-importance than actually helping people.
So, to our "divine messenger" friend: If you're really so concerned about people's suffering, why don't you try something more practical, like volunteering at a soup kitchen or donating to a charity? And while you're at it, maybe consult a dentist about your dental implants. They might be able to tell you something that doesn't involve celestial beings and electrostatic fields.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
XenaLives
2 days ago
Hot Features
Premium
